J&J Settlement With States Not Likely To Be Precedent In OTC Space
Executive Summary
J&J's agreement with 42 states and Washington, D.C. is its latest cost from widespread GMP problems that prompted recalls and led to a 2011 FDA consent decree. But the unusual combination of factors suggest more such state actions are unlikely to follow.